Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25481059 | 0.90 | ALDH1A1 (0.51) | ALDH1A1HRH3ACHERAD52RAB9A | |
| SCHEMBL25481043 | 0.88 | ALDH1A1 (0.43) | ALDH1A1HRH3ACHERAD52RAB9A | |
| SCHEMBL25109387 | 0.87 | ALDH1A1 (0.43) | ALDH1A1HRH3ACHERAD52RAB9A | |
| SCHEMBL25110381 | 0.87 | ALDH1A1 (0.50) | ALDH1A1HRH3ACHERAD52RAB9A | |
| SCHEMBL25110371 | 0.86 | MEN1 (0.51) | ALDH1A1HRH3ACHERAD52MEN1 | |
| SCHEMBL25110359 | 0.85 | ALDH1A1 (0.48) | ALDH1A1HRH3RAB9ANPC1TP53 | |
| SCHEMBL25481054 | 0.84 | HRH3 (0.45) | ALDH1A1HRH3ACHERAD52MEN1 | |
| SCHEMBL25108464 | 0.83 | SIGMAR1 (0.48) | ALDH1A1HRH3RAB9ANPC1TP53 | |
| SCHEMBL25109372 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HRH3ACHERAD52RAB9A | |
| SCHEMBL24170803 | 0.79 | LMNA (0.54) | ALDH1A1HRH3RAB9ANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | ALDH1A1 3473/4885HRH3 1734/4885ACHE 3617/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | ALDH1A1 3736/4885HRH3 1490/4885ACHE 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.